Compare JFU & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | NEPH |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.7M | 37.7M |
| IPO Year | 2018 | 2004 |
| Metric | JFU | NEPH |
|---|---|---|
| Price | $3.08 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.2K | ★ 32.6K |
| Earning Date | 12-09-2022 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ $1.43 | $369.50 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $1.25 | $2.66 |
| 52 Week High | $9.48 | $6.42 |
| Indicator | JFU | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 57.72 |
| Support Level | $2.65 | $3.64 |
| Resistance Level | $4.79 | $3.78 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 7.07 | 85.23 |
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.